356 related articles for article (PubMed ID: 23831921)
1. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
Fernandez-Mercado M; Burns A; Pellagatti A; Giagounidis A; Germing U; Agirre X; Prosper F; Aul C; Killick S; Wainscoat JS; Schuh A; Boultwood J
Haematologica; 2013 Dec; 98(12):1856-64. PubMed ID: 23831921
[TBL] [Abstract][Full Text] [Related]
2. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
[TBL] [Abstract][Full Text] [Related]
3. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
4. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.
Pich A; Godio L; Riera L; Cavaliere C; Kerim S; Bonello L; Francia di Celle P
Ann Hematol; 2016 Feb; 95(3):525-7. PubMed ID: 26750119
[No Abstract] [Full Text] [Related]
7. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
8. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Capodanno I; Neri A; Morabito F; Vigna E; Gentile M
Eur J Haematol; 2024 Jun; 112(6):860-869. PubMed ID: 38294126
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
Wang L; Fidler C; Nadig N; Giagounidis A; Della Porta MG; Malcovati L; Killick S; Gattermann N; Aul C; Boultwood J; Wainscoat JS
Haematologica; 2008 Jul; 93(7):994-1000. PubMed ID: 18508791
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
Kulasekararaj AG; Smith AE; Mian SA; Mohamedali AM; Krishnamurthy P; Lea NC; Gäken J; Pennaneach C; Ireland R; Czepulkowski B; Pomplun S; Marsh JC; Mufti GJ
Br J Haematol; 2013 Mar; 160(5):660-72. PubMed ID: 23297687
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes.
Meggendorfer M; Haferlach C; Kern W; Haferlach T
Haematologica; 2017 Sep; 102(9):1502-1510. PubMed ID: 28642303
[TBL] [Abstract][Full Text] [Related]
13. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Chesnais V; Renneville A; Toma A; Lambert J; Passet M; Dumont F; Chevret S; Lejeune J; Raimbault A; Stamatoullas A; Rose C; Beyne-Rauzy O; Delaunay J; Solary E; Fenaux P; Dreyfus F; Preudhomme C; Kosmider O; Fontenay M;
Blood; 2016 Feb; 127(6):749-60. PubMed ID: 26626993
[TBL] [Abstract][Full Text] [Related]
14. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).
Makishima H; Rataul M; Gondek LP; Huh J; Cook JR; Theil KS; Sekeres MA; Kuczkowski E; O'Keefe C; Maciejewski JP
Leuk Res; 2010 Apr; 34(4):447-53. PubMed ID: 19758696
[TBL] [Abstract][Full Text] [Related]
15. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.
Jerez A; Gondek LP; Jankowska AM; Makishima H; Przychodzen B; Tiu RV; O'Keefe CL; Mohamedali AM; Batista D; Sekeres MA; McDevitt MA; Mufti GJ; Maciejewski JP
J Clin Oncol; 2012 Apr; 30(12):1343-9. PubMed ID: 22370328
[TBL] [Abstract][Full Text] [Related]
16. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
Mallo M; Cervera J; Schanz J; Such E; García-Manero G; Luño E; Steidl C; Espinet B; Vallespí T; Germing U; Blum S; Ohyashiki K; Grau J; Pfeilstöcker M; Hernández JM; Noesslinger T; Giagounidis A; Aul C; Calasanz MJ; Martín ML; Valent P; Collado R; Haferlach C; Fonatsch C; Lübbert M; Stauder R; Hildebrandt B; Krieger O; Pedro C; Arenillas L; Sanz MÁ; Valencia A; Florensa L; Sanz GF; Haase D; Solé F
Leukemia; 2011 Jan; 25(1):110-20. PubMed ID: 20882045
[TBL] [Abstract][Full Text] [Related]
17. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
Ebert BL
Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
[TBL] [Abstract][Full Text] [Related]
18. Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
Scharenberg C; Giai V; Pellagatti A; Saft L; Dimitriou M; Jansson M; Jädersten M; Grandien A; Douagi I; Neuberg DS; LeBlanc K; Boultwood J; Karimi M; Jacobsen SE; Woll PS; Hellström-Lindberg E
Haematologica; 2017 Mar; 102(3):498-508. PubMed ID: 27884971
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
20. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.
McGraw KL; Zhang LM; Rollison DE; Basiorka AA; Fulp W; Rawal B; Jerez A; Billingsley DL; Lin HY; Kurtin SE; Yoder S; Zhang Y; Guinta K; Mallo M; Solé F; Calasanz MJ; Cervera J; Such E; González T; Nevill TJ; Haferlach T; Smith AE; Kulasekararaj A; Mufti G; Karsan A; Maciejewski JP; Sokol L; Epling-Burnette PK; Wei S; List AF
Blood Cancer J; 2015 Mar; 5(3):e291. PubMed ID: 25768405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
